Combination AAV therapy with galectin-1 and SOD1 downregulation demonstrates superior therapeutic effect in a severe ALS mouse model

MLA

Megan C. Baird, et al. “Combination AAV Therapy with Galectin-1 and SOD1 Downregulation Demonstrates Superior Therapeutic Effect in a Severe ALS Mouse Model.” Molecular Therapy: Methods & Clinical Development, vol. 32, no. 3, Sept. 2024. EBSCOhost, https://doi.org/10.1016/j.omtm.2024.101312.

APA

Megan C. Baird, Shibi B. Likhite, Tatyana A. Vetter, Joseph R. Caporale, Holly B. Girard, Florence S. Roussel, Abigail E. Howard, Maura K. Schwartz, Addison R. Reed, Abuzar Kaleem, Xiaojin Zhang, & Kathrin C. Meyer. (2024). Combination AAV therapy with galectin-1 and SOD1 downregulation demonstrates superior therapeutic effect in a severe ALS mouse model. Molecular Therapy: Methods & Clinical Development, 32(3). https://doi.org/10.1016/j.omtm.2024.101312

Chicago

Megan C. Baird, Shibi B. Likhite, Tatyana A. Vetter, Joseph R. Caporale, Holly B. Girard, Florence S. Roussel, Abigail E. Howard, et al. 2024. “Combination AAV Therapy with Galectin-1 and SOD1 Downregulation Demonstrates Superior Therapeutic Effect in a Severe ALS Mouse Model.” Molecular Therapy: Methods & Clinical Development 32 (3). doi:10.1016/j.omtm.2024.101312.